From: Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study
Study number | Age group at first dose (years) | Gender | Clinical background, including possible risk factors for UTI | Urine culture result | Total number of 3Â g fosfomycin doses | eGFR at baseline | Any reported side-effects | Notes on outcome |
---|---|---|---|---|---|---|---|---|
FOS015 | 80–89 | M | Vasculopath; bilateral below knee amputations. Recurrent E. coli bacteraemia with unclear source despite extensive investigation. Relapsed after a treatment course of iv ertapenem | ESBL E. coli | 36 | 79 | None reported | Well when reviewed following end of treatment course; discharged from clinic |
FOS038 | 60–69 | M | History of recurrent UTI for > 10 years. Dilatation for urethral stricture, followed by TURP. Prostate cancer confirmed; treated post-op with radiotherapy | ESBL E. coli | 81 | >90 | None reported | Interval free of infection, followed by recurrence of UTI (different organisms) |
FOS060 | 60–69 | M | Relapsing urosepsis following TRUS biopsy (negative for prostate cancer). Presumed prostatitis as focus of infection. | ESBL E. coli | 33 | 79 | Reported shortness of breath during treatment, but thought unlikely to be related to fosfomycin | Well when reviewed following end of treatment course; discharged from clinic |
FOS098 | 70–79 | M | Transitional cell carcinoma treated with nephrouretectomy. Regular surveillance cystoscopy complicated by recurrent UTI; recurred after completing treatment with meropenem. | ESBL E. coli | 49 | 41 | None reported | Interval free of infection, followed by recurrence and re-treatment with fosfomycin |
FOS140 | 40–49 | F | Recurrent UTI following sling procedure and botox treatment for stress/urge incontinence. Intermittent self-catheterisation. Good symptomatic relief with fosfomycin. | E. coli | 15 | >90 | None reported | Ongoing prophylaxis while awaiting urogynaecology surgery |